Global Thematic Partners LLC reduced its position in shares of NuVasive, Inc. (NASDAQ:NUVA) by 1.0% in the 1st quarter, Holdings Channel reports. The firm owned 65,415 shares of the medical device company’s stock after selling 687 shares during the period. Global Thematic Partners LLC’s holdings in NuVasive were worth $3,715,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. purchased a new stake in NuVasive in the fourth quarter valued at $114,000. Retirement Systems of Alabama increased its stake in shares of NuVasive by 0.3% during the fourth quarter. Retirement Systems of Alabama now owns 66,672 shares of the medical device company’s stock worth $3,304,000 after acquiring an additional 219 shares during the period. Redmile Group LLC acquired a new position in shares of NuVasive during the third quarter worth about $31,210,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of NuVasive by 10.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,488 shares of the medical device company’s stock worth $173,000 after acquiring an additional 317 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in shares of NuVasive during the third quarter worth about $209,000.
A number of research analysts have recently issued reports on the stock. Credit Suisse Group assumed coverage on shares of NuVasive in a research note on Monday, December 17th. They set an “outperform” rating and a $66.00 price target on the stock. Cantor Fitzgerald reiterated a “hold” rating and issued a $50.00 price target on shares of NuVasive in a research report on Monday, February 11th. UBS Group lowered their price target on shares of NuVasive from $54.00 to $42.00 and set a “sell” rating on the stock in a research report on Tuesday, January 8th. Morgan Stanley lowered their price target on shares of NuVasive from $73.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. Finally, Zacks Investment Research lowered shares of NuVasive from a “hold” rating to a “sell” rating in a research report on Thursday, February 7th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the stock. NuVasive has a consensus rating of “Hold” and a consensus target price of $66.64.
NuVasive (NASDAQ:NUVA) last announced its quarterly earnings data on Wednesday, February 20th. The medical device company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.06. The business had revenue of $288.30 million for the quarter, compared to the consensus estimate of $290.85 million. NuVasive had a net margin of 1.13% and a return on equity of 14.60%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.56 earnings per share. Equities analysts expect that NuVasive, Inc. will post 2.25 EPS for the current fiscal year.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Further Reading: Do stock splits help investors?
Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.